Vera Therapeutics, Inc. Class A Common Stock
VERAVera Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. The company is dedicated to advancing novel biologics targeting specific pathways to address unmet medical needs, aiming to improve patient outcomes in conditions such as kidney diseases and other chronic inflammatory disorders.
Company News
Vera Therapeutics plans to raise approximately $261 million through a public offering of 6,138,108 shares of Class A common stock at $42.50 per share, with underwriters led by J.P. Morgan and Goldman Sachs.
The BK virus infection market is experiencing growth due to increasing organ transplant procedures, lack of FDA-approved drugs, and rising awareness. Innovative therapies and personalized medicine approaches are emerging to address treatment challenges.
Vera Therapeutics submitted a Biologics License Application to the FDA for atacicept, a potential treatment for IgA Nephropathy, after successful Phase 3 trial results showing significant proteinuria reduction. The drug targets B-cell cytokines and could potentially be approved in 2026.
Vera Therapeutics reported a wider net loss of $76.5 million in Q2 2025, with significant progress on its lead drug atacicept for treating Immunoglobulin A Nephropathy (IgAN). The company showed positive clinical trial results and plans to submit a Biologics License Application to the FDA in Q4 2025.
Vera Therapeutics granted stock options and restricted stock units to 15 new employees, with options to purchase 133,500 shares and RSUs for 73,695 shares, vesting over four years.
